EcoDrugPlus

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSFHEG00000017424
Gene Symbol: FGFR2
1 Cross references
217 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSFHEG00000007853
Gene Symbol: FGFR3
3 Cross references
191 Possible Orthologues:

Fms Related Tyrosine Kinase 1

Ensembl ID : ENSFHEG00000016507
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Tyrosine Kinase 4

Ensembl ID : ENSFHEG00000009109
Gene Symbol: FLT4
3 Cross references
197 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSFHEG00000003211
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Alpha

Ensembl ID : ENSFHEG00000003033
Gene Symbol: LOC105923429
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSFHEG00000020966
Gene Symbol: LOC105916801
2 Cross references
340 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSFHEG00000005504
Gene Symbol: FRK
3 Cross references
215 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSFHEG00000013995
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Galectin-3

Ensembl ID : ENSFHEG00000003903
Gene Symbol: LOC105932928
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSFHEG00000004328
Gene Symbol: LOC105935679
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSFHEG00000008443
Gene Symbol: LOC105919487
2 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).